

Claim Amendments:

Claims 1 to 21 (Cancelled)

Claim 22. (Previously presented) A compound which binds the G-quadruplex structure of a telomer, having the following general formula:

nitrogen-containing aromatic ring – NR₃ – distribution agent – NR'₃ – aromatic ring

wherein

- the nitrogen-containing aromatic ring represents:
 - ◊ a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen, a short-chain C1-C4 alkyl, or alkoxy radical, or
 - ◊ a quinoline possessing a nitrogen atom in quaternary form;
 - the aromatic ring represents
 - ◊ a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen, a short-chain C1-C4 alkyl, or alkoxy radical, or
 - ◊ a quinoline possessing a nitrogen atom in quaternary form;
 - R₃ and R'₃, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical;
 - the distribution agent represents:
 - a diazine group optionally substituted with an alkyl radical having 1 to 4 carbon atoms, a thio, oxy or amino radical which are themselves optionally substituted with one or more short-chain alkyl chains containing 1 to 4 carbon atoms or a halogen atom;
- or a salt of said compound.

Claim 23. (Cancelled)

Claim 24. (Previously presented) A compound according to Claim 22, wherein the diazine group is a pyrimidine.

Claim 25. (Previously presented) A method of inhibiting telomerase activity, comprising administering an effective amount of a compound according to claim 22 to a patient, wherein the level of telomerase activity in the patient following administration is reduced relative to the level of telomerase activity existing prior to the administration.

Claim 26. (Previously presented) A method of treating lung cancer, comprising administering a therapeutically effective amount of a compound according to claim 22 to a patient in need of such treatment, wherein the level of telomerase activity following the administration is reduced relative to the level of telomerase activity existing prior to the administration.

Claim 27. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 22, and a pharmaceutically acceptable carrier.

Claims 28-30 (Cancelled)

Claim 31. (Previously presented) The method according to Claim 34, wherein each of the compounds is administered simultaneously, separately, or sequentially.

Claim 32. (Previously presented) The method according to Claim 35, wherein each of the compounds is administered simultaneously, separately, or sequentially.

Claim 33. (Previously presented) The method according to Claim 36, wherein each of the compounds and radiation are administered simultaneously, separately, or sequentially.

Claim 34. (Currently amended) The method according to Claim 25 further comprising administering an anticancer compound selected from the group consisting of alkylating agents, cisplatin, carboplatin, oxaliplatin, antibiotic agents, antimicrotubule agents, anthracyclines, ~~group I and II topoisomerases, fluoropyrimidines,~~ 5-azacytidine, cytarabine, gemcitabine, 6-mercaptopurine, 6-thioguanine, pentostatin, cytarabine, fludarabine phosphate methotrexate,

folinic acid, L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, irinotecan, topotecan, dexrazoxane, amifostine, and herceptin, ~~oestrogenic hormones and androgenic hormones.~~

Claim 35. (Currently Amended) The method according to Claim 25-Claim 34, ~~wherein the anticancer compound is~~ further comprising administering an anticancer agent selected from the group consisting of cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulfan, thiotepa, prednimustine, carmustine, lomustine, semustine, streptozotocin, decarbazine, temozolomide, procarbazine, hexamethylmelamine, cisplatin, carboplatin, oxaliplatin, bleomycin, mitomycin, dactinomycin, vinblastine, vincristine, vindesine, vinorelbine, paclitaxel, docetaxel, doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone, losoxantrone, etoposide, teniposide, amsacrine, irinotecan, topotecan, tomudex, 5-fluorouracil, UFT, floxuridine, 5-azacytidine, cytarabine, gemcitabine, 6-mercaptopurine, 6-thioguanine, pentostatin, cytarabine, fludarabine, phosphate methotrexate, folinic acid, L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, dexrazoxane, amifostine, and herceptin.

Claim 36. (Previously presented) The method according to Claim 25, wherein said compound is administered in combination with radiation.